We’re on a mission to make early liver cancer detection as routine as a cholesterol test.
Every year, over 30,000 Americans die from liver cancer. The majority of those deaths were potentially preventable — not because we lack treatment options, but because the cancers were found too late to treat.
MoleculeDx was founded to close this gap. We combined next-generation genomic sequencing with clinical-grade AI to create a blood test that’s simple enough for any at-risk patient to use, accurate enough for physicians to trust, and affordable enough for widespread adoption.
Our Fusion-detect™ platform doesn’t just screen — it catches cancers at the stage when treatment can still save lives.
When liver cells become cancerous, they produce characteristic fusion gene events — chromosomal rearrangements that generate novel protein sequences. These are detectable in the blood years before a tumor is visible on imaging.
Our test identifies specific chromosomal fusion events in circulating tumor DNA — a molecular fingerprint that is highly specific to hepatocellular carcinoma.
Our Fusion-detect™ AI is trained on 50,000+ clinical samples. It classifies results with 95.0% accuracy, removing the subjectivity that plagues many diagnostic tests.
All samples are processed in our CLIA-certified laboratory under strict federal standards. Every result is reviewed by a licensed clinical pathologist before release.
Booking takes 2 minutes. A phlebotomist can be at your door within 48 hours. Don’t wait for symptoms that may never come.
You may benefit from regular liver cancer screening if you have one or more of these conditions.
Our mission is to make precise, evidence-based cancer testing accessible, affordable and timely for every patient — and to give doctors, hospitals and labs the digital tools they need to support that goal.
Moleculedx was founded with the goal of bridging the gap between modern molecular diagnostics and everyday clinical practice. Specific incorporation details are available on request from our partnerships team.
Moleculedx is a healthcare technology and diagnostics company. We operate accredited testing labs, run a digital booking platform, and partner with hospitals, clinics, doctors and home-collection providers across the country.
Moleculedx labs operate in line with applicable national accreditation standards for medical laboratories. Specific accreditations (such as NABL, ISO and equivalent) for each lab partner are listed on the corresponding lab profile.
Moleculedx is led by an experienced team of clinicians, molecular biologists, technologists and operators. Detailed leadership profiles are available on the Leadership section of the About page.
Every test follows defined standard operating procedures, internal and external quality controls, sample chain-of-custody tracking, and review by qualified pathologists. Quality is governed by our internal Quality Management System.
Patient data is encrypted, access-controlled, and stored in compliance with applicable healthcare data privacy laws. Only authorized clinical and operations personnel can access patient records, and audit logs track every access event.
Yes. Moleculedx is committed to advancing cancer diagnostics through clinical research, real-world data studies and academic collaboration. Selected publications and white papers are listed on the Research section of the About page.
Open positions are listed on the Careers page. We hire across clinical, scientific, technology and operations functions. You can also write to careers@moleculedx.com to express interest in future roles.
For general queries write to hello@moleculedx.com, for partnerships partners@moleculedx.com, and for support support@moleculedx.com. Contact numbers and addresses are available on the Contact page.
© 2026 MoleculeDx Inc. All rights reserved.
This test is not a substitute for medical diagnosis. Consult your physician with all results.
